Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02650414 · ClinicalTrials.gov registry record · Phase 1
CD22 Redirected Autologous T Cells for ALL
A Phase 1 study of B-cell Lymphomas and B Cell Leukemias, sponsored by University of Pennsylvania.
- Active
- Registry status
- Phase 1
- Development phase
- 41
- Enrollment target
- 1
- Study location
NCT02650414: Active Phase 1 study of B-cell Lymphomas and B Cell Leukemias, sponsored by University of Pennsylvania.
NCT02650414 is a Phase 1 study of B-cell Lymphomas and B Cell Leukemias that is active but no longer recruiting, run by University of Pennsylvania. The registered enrollment target is 41 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (32% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02650414, a Phase 1 study of B-cell Lymphomas and B Cell Leukemias, is active but no longer recruiting, sponsored by University of Pennsylvania.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 41 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a pilot study to determine the feasibility and safety of a single dose of autologous T cells expressing CD22 chimeric antigen receptors expressing tandem TCR-ζ and 4-1BB signaling domains (CART22/CART22-65s cells) in pediatric and young adult subjects with relapsed or refractory B cell acute lymphoblastic leukemia.
Primary Outcome
Grade 3 and higher toxicity rate (toxicity possibly attributed to CART22 or CART22-65s) that is unmanageable, unexpected and unrelated to chemotherapy.
Conditions Studied
Interventions
- BIOLOGICAL Cohort 1
- BIOLOGICAL Cohorts 2
- BIOLOGICAL Cohort 3
Study Locations (1)
Pennsylvania
- Children's Hospital of Philadelphia - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2016-01-13 |
| Est. Completion | 2037-12 |
| Phase | Phase 1 |
What the registry record for NCT02650414 still lists
NCT02650414 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 41 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (32% lower).
The record links to 2 conditions, with B-cell Lymphomas appearing as the primary indexed condition, and to 3 interventions - of which Cohort 1 is the first listed.
NCT02650414 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT02650414 about?
NCT02650414 is a clinical study titled "CD22 Redirected Autologous T Cells for ALL". This is a pilot study to determine the feasibility and safety of a single dose of autologous T cells expressing CD22 chimeric antigen receptors expressing tandem TCR-ζ and 4-1BB signaling domains (CART22/CART22-65s cells) in pediatric and young adult subjects with relapsed or refractory B cell acute...
What is the current status of trial NCT02650414?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 41 participants. The study started on 2016-01-13. Estimated completion is 2037-12.
What conditions does trial NCT02650414 study?
This clinical trial studies the following conditions: B-cell Lymphomas, B Cell Leukemias.
What interventions are being tested in trial NCT02650414?
The interventions under investigation include: Cohort 1 (BIOLOGICAL), Cohorts 2 (BIOLOGICAL), Cohort 3 (BIOLOGICAL).
Who is sponsoring clinical trial NCT02650414?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02650414 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for B-cell Lymphomas
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02650414's enrollment target sits among peer trials
41 1125th of 2000 higher than 871 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03449238 · 41 participants · Phase 1
Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients
- NCT03900793 · 41 participants · Phase 1
Losartan + Sunitinib in Treatment of Osteosarcoma
- NCT04082520 · 41 participants · Phase 2
Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy
- NCT04220190 · 41 participants · Phase 2
RAPA-501 Therapy for ALS
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI